At Montefiore Einstein Cardiology, we know that providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.
2022 Highlights
As challenging as 2022 was, Montefiore Einstein Cardiology made impressive strides in research, medical innovation and care. In addition to the many lifesaving procedures we performed, we broadened our footprint by establishing new outpatient and specialty clinics and contributing important scientific studies.
DATA & STATISTICS
catheterizations
instances of cardiac arrhythmia management
percutaneous valve replacement procedures
noninvasive cardiac imaging studies
Innovations and achievements
Dr. Leandro Slipczuk (Cardiac Imaging and Lipid Metabolism), in collaboration with Dr. Molly Fisher (Nephrology), Dr. Sasa Vukelic (Heart Failure and Transplant) and David Carruthers (Endocrinology), leads a program that provides treatment for hundreds of patients with complex disorders of lipid metabolism, uncontrolled diabetes or kidney disease, and who have or are at risk for cardiovascular disease.
We are the one and only destination in New York for bloodless heart transplantation and one of the most active programs attending patients in cardiogenic shock. Our heart transplant survival rates rival the best in the nation.
Our department utilizes the most advanced, novel technologies and approaches available to manage complex patients and guide structural interventions. In 2022 our team performed the first in-human completely percutaneous chordal replacement for degenerative mitral valve insufficiency. Our high success rates, excellent outcomes have allow us to increase our volume of procedures by almost 30% over the previous year, becoming one of the largest program in the country.
Together with the routine use of intracoronary imaging and the latest technologies to approach complex intracoronary lesions, such as intravascular lithotripsy, our management of one of the country’s busiest ST-elevation myocardial infarction (STEMI) programs allows our patients to undergo complete myocardial revascularization with excellent outcomes and noticeable improvement in their quality of life.
In 2022, we transmitted more than 100 live grand round lectures. Our faculty participated in over 50 national and international meetings and published more than 200 original articles in peer-reviewed journals. Our conferences were transmitted and watched around the world by thousands of healthcare professionals.
Research Review
In 2022, we published over 200 scientific articles across a variety of topics.
Clinical Trials
We participated in over 30 clinical trials in 2022, spanning from novel drugs through advanced devices for the treatment of heart failure, valvular heart disease and arrhythmias. Our investigators performed several first-in-human procedures that sought to offer better treatment options for patients with heart disease.
We expanded our footprint, opening Montefiore Einstein Advanced Care - Westchester and new outpatient clinics at White Plains Hospital, Wakefield Campus and Montefiore Heart Failure Center at Nyack Hospital. We are also finalizing plans for a comprehensive heart failure initiative, which will include specialty clinics for amyloid, sarcoid, hypertrophic cardiomyopathy and pulmonary hypertension, cardiac intensive care consultations at Nyack Hospital and a new catheterization laboratory. This initiative marks a major step toward solidifying Montefiore’s footprint and heart failure expertise in New York’s Hudson Valley region.
At Montefiore Einstein Cardiology, we know that providing patients with the best possible care includes teamwork and trust. We work closely with our valued referring physicians to ensure open communication and reliable expertise.
Delia Osborne
Assistant Director
dosborne@montefiore.org
Montefiore Einstein Center for Heart and Vascular Care
Montefiore.org
Einsteinmed.org
